Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06787612 · ClinicalTrials.gov registry record · Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06787612 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 220 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06787612, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Cemiplimab
- DRUG PLD
- DRUG Ubamatamab
- DRUG Fianlimab
Study Locations (20)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- Tampa General Hospital Cancer Institute - Tampa
California
- UC San Diego Health - La Jolla
- Cedars Sinai Medical Center - Los Angeles
Gyeonggi-do
- National Cancer Center - Gyeonggi-do
- Seoul National University Bundang Hospital - Seongnam-si
Alabama
- The University of Alabama at Birmingham - Birmingham
Illinois
- University of Chicago - Chicago
Kansas
- The University of Kansas Cancer Center - Westwood
Kentucky
- Norton Cancer Institute, St. Matthews Clinic - Louisville
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2028-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06787612
The ClinicalTrials.gov registry entry for NCT06787612 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (70% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT06787612 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, Gyeonggi-do.
Frequently Asked Questions
What is clinical trial NCT06787612 about?
NCT06787612 is a clinical study titled "Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer". This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-ca...
What is the current status of trial NCT06787612?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2025-05-28. Estimated completion is 2028-12-07.
What conditions does trial NCT06787612 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06787612?
The interventions under investigation include: Bevacizumab (DRUG), Cemiplimab (DRUG), PLD (DRUG), Ubamatamab (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT06787612?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06787612 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.